Compare Jones Lang LaSalle Inc (JLL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs TG Therapeutics Inc — how do they compare? Jones Lang LaSalle Inc trades at $362.41 (market cap $16.72B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Jones Lang LaSalle Inc is far larger — about 2.2× TG Therapeutics Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| JLL | TGTX | |
|---|---|---|
Market Cap | $16.72B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $373.24 | $59.06 |
52-Week Low | $280.16 | $26.94 |
Enterprise Value | $19.48B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $362.74, up 1.51% today and near its 52-week high, with a bullish technical signal supported by a golden cross. The company reported strong Q2 2026 earnings, beating estimates with EPS of $5.26 versus $4.56 expected, driven by leasing and capital markets growth. Revenue reached $26.12B in 2025, with net income margin improving to 3.64%. Operating cash flow surged to $1.19B in 2025, reflecting robust financial health. Analyst consensus is a Buy with a $391.50 price target, indicating potential upside from current levels.
The outlook for JLL remains positive given consistent earnings beats, revenue growth, and strong cash flow generation. Key opportunities include momentum in advisory services and recurring revenue streams. Risks involve economic sensitivity to real estate cycles and competitive pressures. Institutional interest is solid, with firms like Bank of America increasing holdings. The stock's valuation at a P/E of 17.43 appears reasonable relative to growth prospects, supporting a constructive view for investors seeking exposure to commercial real estate services.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
